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Sir,
This letter responds to editorials by SW Duffy and JM Reich
commenting on our recent publication ‘Cost of a 5-year lung
cancer survivor: symptomatic tumour identification vs proactive
computed tomography screening’ (Castleberry et al., 2009; Duffy,
2009; Reich, 2009).
Although we appreciate their efforts to analyse our methods and
conclusions, we believe that the comments reflect preconceptions
and misunderstandings about lung cancer screening. Although our
manuscript clearly states that the estimates are based on screening
within the context of the International Early Lung Cancer Action
P r o g r a m( I E L C A P )P r o t o c o l ,n e i t h e rD rD u f f yn o rD rR e i c h
reference this document in their editorials or appear to appreciate
its implications (IELCAP, 2009). This is an important omission.
Furthermore, Dr Reich’s comments contain a number of inaccurate
statements regarding the published results of lung cancer screening.
We thank Dr Duffy for his kind remarks on the innovative
nature of our method of analysis. To address his comment that
survival of screen-detected cases is known to be potentially
affected by lead-time and length-time biases, we point out that
published IELCAP data demonstrate a flat actuarial survival curve
with no drop in survival consistent with delayed lead-time deaths
out to 10 years (Henschke et al, 2006). IELCAP data also show an
incidence of rapidly growing interval lung cancers occurring
between annual CT screens of less than 1%, inconsistent with
substantial length-time bias (Carter et al, 2007).
The primary critique of both editorialists is that our cost
estimates may be inaccurate because we did not factor substantial
proportions of theoretically non-lethal, overdiagnosed lung
cancers in our model. Although Dr Duffy states that ‘it is difficult
to avoid the conclusion that there must be some overdiagnosis in
CT screening’, he hedges ‘if the hypothesis of a sizable population
of indolent lung tumors is correct, this is a fascinating
phenomenon, given the very poor prognosis of symptomatic
disease’. We believe that his scepticism is judicious.
Reich, however, asks the reader to be sufficiently credulous to
accept that there might be sufficiently large numbers of non-lethal
screen-detected cancers that a double-arm trial could show a
fivefold difference in survival (between symptomatic lung cancers
in the US or British national data (8–15%) and 80% actuarial
10-year survival in the IELCAP study) and yet no reduction in lung
cancer-specific mortality.
To support this hypothesis, Reich estimates that the incidence of
overdiagnosed lung cancer is around 50%. In fact, to explain this
markedly improved survival without reduced deaths, more than
75% of CT-screen detected lung cancers would have to be non-
lethal.
In the case of prostate cancer, for which the existence of a
substantial number of very slow-growing cancers has been well
established, a recent publication from the National Cancer
Institute (NCI) estimates that the incidence of overdiagnosis is
approximately 23% (Welch and Albertsen, 2009). Reich therefore
asks the reader to accept that the incidence of overdiagnosed lung
cancer could double that of prostate cancer. But there is no reliable
direct evidence to document any substantial lung cancer over-
diagnosis. Three 1986 publications from Alvan Feinstein
describing ‘postmortem-surprise lung cancers’ were funded by
the notorious Council for Tobacco Research and are often cited in
defence against medical monitoring lawsuits (McFarlane et al,
1986a,b, 1987). Symptom-detected but untreated stage I patients
die, almost always, within 5 years (Raz et al, 2007). The same is
true of untreated patients detected by screening roentgenograms
and CT scans (Sobue et al, 1992).
Reich’s hypothesis would be cause for amusement if not
for the cost. We refer not to the $200 million price tag of
the NCI’s National Lung Screen Trial, but to the unneces-
sary suffering and death of thousands of individuals from lung
cancer who might have been salvaged by screening, between
today and the publication of prospective randomised trials. Is
this a reasonable and humane cost to refute a preposterous
hypothesis?
We suspect that a mindset that would consider such cost
justifiable is what led Arthur Golleb to characterise epidemiology
as ‘the practice of medicine without the tears’.
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